PET/MRI of Primary Sclerosing Cholangitis
ConditionPSC
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-99
SponsorMassachusetts General Hospital
About this trial
This study aims to use positron emission tomography (PET)/magnetic resonance imaging (MRI) to diagnose and quantify PSC-related biliary tract fibrosis and to improve upon the currently available non-invasive diagnostic capabilities by investigating the ability of combined PET/MRI to detect and quantify fibrosis using a novel collagen-binding radiotracer. Specifically, the investigators will be comparing \[68Ga\]CBP8- and \[18F\]-FAPI-74 PET/MRI to a liver transient elastography scan in the diagnosis of biliary tree fibrosis.
Eligibility criteria
Qualifiers
Established clinical diagnosis of large duct PSC
Participants receiving treatment for IBD are allowed if on a stable dose from screening and expected to remain stable for the duration of the study
Serum AST and ALT concentration ≤ 8 times the upper limit of normal
Disqualifiers
Other causes of chronic liver disease, including secondary sclerosing cholangitis or viral, metabolic, or alcoholic liver disease, as assessed clinically
Known or suspected overlapping clinical or histologic diagnosis of autoimmune hepatitis
Subjects less than 18 years of age or greater than 85 years of age.
Subjects with electrical implants, such as cardiac pacemakers or perfusion pumps.
Trial design
Treatments tested in this trial
- Radiotracer Injection
- Contrast Media, Magnetic Resonance
- Imaging
Treatment groups
10 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov